Efrat Dotan is an Oncology physician affiliated with Fox Chase Cancer Center. OpenAlex indexes 257 publications with 8,978 citations (h-index 35); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
333 Cottman Avenue
Fox Chase Cancer Center
Philadelphia, PA 19111
Telephone
215-728-6900Registry record last updated 9 Apr 2018.
Clinical trials
- Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver
Sponsor: Fox Chase Cancer Center
- Telomere Length in Predicting Toxicity in Older Patients With Stage III-IV Colorectal Cancer Undergoing Chemotherapy
Sponsor: Fox Chase Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
17 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20252 payments
- Amgen Inc.Program year20251 payment
- JAZZ PHARMACEUTICALS INC.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
33.8%Serotonin-3 Receptor Antagonist18.3%Ondansetron Hcl100%Part D≥12 patientsProton pump inhibitor15.5%Pantoprazole Sodium100%Part D<11 patientsBlood & clotting
28.2%Factor Xa inhibitor28.2%Eliquis100%Part D<11 patientsNervous system
19.7%Phenothiazine19.7%Prochlorperazine Maleate100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2021–2022 per NIH RePORTER. The latest:
- Neoadjuvant Stroma Modification in Pancreatic Cancer
Research Inst of Fox Chase Can Ctr
FY2022$249,135R21CA252535 - Neoadjuvant Stroma Modification in Pancreatic Cancer
Research Inst of Fox Chase Can Ctr
FY2021$210,508R21CA252535
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Cardiovascular Concerns, Cancer Treatment, and Biological and Chronological Aging in Cancer
JACC CardioOncology
2024 - Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Elizabeth Plimack, MD
Fox Chase Cancer Center
Martin Edelman, MD
Fox Chase Cancer Center
Shazia Nakhoda, MD
Fox Chase Cancer Center
Hossein Borghaei, MD
Fox Chase Cancer Center
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”